nd Chris Rochet, PhD, of Purdue
University will determine which modified forms of alpha-synuclein have the
greatest effects on aggregation and toxicity to dopamine neurons. A third
investigator, Deniz Kirik, MD, PhD, of Lund University in Sweden, will test
the hypothesis that the toxicity of alpha-synuclein may be enhanced by
interaction with dopamine itself, which might help further explain the
selective vulnerability of these cells in PD.
The four investigators awarded under the LRRK2 challenge all seek to
test whether an abnormal increase in LRRK2's enzymatic function triggers
toxicity. Chenjian Li, PhD, of Weill Medical College of Cornell University
and Zhenyu Yue, PhD, of Mount Sinai School of Medicine are each developing
mice genetically engineered to express mutant forms of the LRRK2 gene,
including a form that lacks enzymatic function, to directly test the
hypothesis. Two other investigators, Romain Zufferey, MD, PhD, of Swiss
Federal Institute of Technology and Andrew West, PhD, of the University of
Alabama at Birmingham, will perform similar studies but will instead
deliver the modified LRRK2 gene directly to brain cells using modified
viruses, technology similar to that used in gene therapy.
Grant abstracts and researcher bios for all projects are available on
the Foundation's Web site, http://www.michaeljfox.org.
About The Michael J. Fox Foundation
Founded in 2000, The Michael J. Fox Foundation for Parkinson's Research
is dedicated to ensuring the development of a cure for Parkinson's disease
within this decade through an aggressively funded research agenda. The
Foundation has funded over $112 million in research to date.
Page: 1 2 Related biology technology :1
|SOURCE Michael J. Fox Foundation|
Copyright©2008 PR Newswire.
All rights reserved
. Pharmasset Appoints Michael Rogers as Chief Development Officer2
. MacroChem Announces Michael Zasloff, M.D., Ph.D. Joins Companys Scientific Advisory Board3
. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors4
. Genstar Names Michael Hurt to Its Strategic Advisory Board5
. Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer6
. Michael Troullis Appointed Chief Financial Officer of Quintiles Transnational Corp.7
. Avon Foundation Announces 2008 Avon Walk for Breast Cancer Schedule8
. A&G Pharmaceutical Receives $870,000 Grant from Avon Foundation to Advance Innovative Blood Diagnostic Test for Early Detection of Breast Cancer9
. eHealth Initiative Foundation Launches Collaborative Research Effort to Improve Drug Safety10
. Genasense(R) Triple Combination Therapy in Advanced Melanoma Presented at Chemotherapy Foundation Symposium11
. John Timberlake, Valeritas Executive Vice President and General Manager, Named Executive of the Year by the Diabetes Foundation